BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Focosi D, Franchini M. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol 2021;28:132-4. [PMID: 33675992 DOI: 10.1016/j.tracli.2021.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Franchini M, Baldanti F, Percivalle E, Ferrari A, Biasi P, Liumbruno GM, Glingani C. Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma. Transfus Clin Biol 2021:S1246-7820(21)00113-0. [PMID: 34391625 DOI: 10.1016/j.tracli.2021.07.006] [Reference Citation Analysis]
2 Beraud M, Goodhue Meyer E, Lozano M, Bah A, Vassallo R, Brown BL. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103355] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Franchini M, Focosi D, Percivalle E, Beccaria M, Garuti M, Arar O, Pecoriello A, Spreafico F, Greco G, Bertacco S, Ghirardini M, Santini T, Schiavulli M, Stefania M, Gagliardo T, Sammartino JC, Ferrari A, Zani M, Ballotari A, Glingani C, Baldanti F. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. Viruses 2022;14:1443. [DOI: 10.3390/v14071443] [Reference Citation Analysis]
4 Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022;:e0020021. [PMID: 35262370 DOI: 10.1128/cmr.00200-21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]